Table 2 Baseline characteristics by sex in paroxysmal AF
Variables | Total (n = 476) | Male (n = 270) | Female (n = 206) | P value |
|---|---|---|---|---|
Age, years, Mean (SD) | 62.1 ± 10.2 | 60.7 ± 11 | 63.8 ± 8.8 | 0.003 |
BMI, kg/m2, Mean (SD) | 25 ± 3.5 | 25 ± 3.4 | 25 ± 3.6 | 0.757 |
AF duration, m (IQR) | 12 (6–48) | 16.5 (6–60) | 12 (4–48) | 0.376 |
Concomitant medical history, n (%) | Â | Â | Â | Â |
 Hypertension | 214 (45) | 120 (44.4) | 94 (45.6) | 0.853 |
 Diabetes mellitus | 48 (10.1) | 18 (6.7) | 30 (14.6) | 0.006 |
 History of stroke/TIA | 25 (5.3) | 15 (5.6) | 10 (4.9) | 0.837 |
 Chronic heart failure | 7 (1.5) | 3 (1.1) | 4 (1.9) | 0.473 |
 Coronary artery disease | 96 (20.2) | 54 (20) | 42 (20.4) | 1.000 |
AAD post-ablation, n (%) | 408 (85.7) | 231 (85.6) | 177 (85.9) | 0.910 |
amiodarone, n (%) | 394 (82.8) | 225 (83.3) | 169 (82.0) | 0.711 |
propafenone, n (%) | 14 (2.9) | 6 (2.2) | 8 (3.9) | 0.288 |
LAD, mm, Mean (SD) | 33.8 ± 5.6 | 34.4 ± 5.5 | 33 ± 5.5 | 0.013 |
LVEDD, mm, Mean (SD) | 47.6 ± 4.5 | 48.7 ± 4.6 | 46.2 ± 4 | < 0.001 |
LVEF, %, Mean (SD) | 57.3 ± 4.1 | 57.1 ± 4.8 | 57.5 ± 3 | 0.578 |
Ablation time, min (IQR) | 116 (87.3–157) | 116.5 (86–157) | 114 (89–157) | 0.835 |
LAV, ml (IQR) | 82 (69–99) | 85.6 (72–101) | 78 (65.4–96) | < 0.001 |
LAVI, ml /m2 (IQR) | 47.1 (40.2–56.6) | 47.1 (39.3–55.3) | 46.5 (41.2–56.8) | 0.444 |
extraPV ablation, n (%) | 83 (16.8) | 42 (15.6) | 41 (19.9) | 0.225 |
Follow-up, m (IQR) | 55 (38–73) | 55 (38–74) | 54.5 (38–72) | 0.796 |
ATa recurrence, n (%) | 163 (34.2) | 101 (37.4) | 62 (30.1) | 0.096 |